| Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia JC Byrd, JR Brown, S O'Brien, JC Barrientos, NE Kay, NM Reddy, ... New England Journal of Medicine 371 (3), 213-223, 2014 | 1938 | 2014 |
| Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study S Stilgenbauer, B Eichhorst, J Schetelig, S Coutre, JF Seymour, T Munir, ... The lancet oncology 17 (6), 768-778, 2016 | 938 | 2016 |
| Immunophenotyping of leukemias using a cluster of differentiation antibody microarray L Belov, O de la Vega, CG dos Remedios, SP Mulligan, ... Cancer research 61 (11), 4483-4489, 2001 | 464 | 2001 |
| Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma T Munir, JR Brown, S O'Brien, JC Barrientos, PM Barr, NM Reddy, ... American journal of hematology 94 (12), 1353-1363, 2019 | 430 | 2019 |
| A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study CS Tam, S Opat, S D'Sa, W Jurczak, HP Lee, G Cull, RG Owen, P Marlton, ... Blood, The Journal of the American Society of Hematology 136 (18), 2038-2050, 2020 | 380 | 2020 |
| Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial S Stilgenbauer, B Eichhorst, J Schetelig, P Hillmen, JF Seymour, S Coutre, ... Journal of Clinical Oncology 36 (19), 1973-1980, 2018 | 344 | 2018 |
| A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European … AC Rawstron, C Fazi, A Agathangelidis, N Villamor, R Letestu, ... Leukemia 30 (4), 929-936, 2016 | 265 | 2016 |
| Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL JR Brown, P Hillmen, S O’brien, JC Barrientos, NM Reddy, SE Coutre, ... Leukemia 32 (1), 83-91, 2018 | 263 | 2018 |
| Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab JC Byrd, P Hillmen, S O’Brien, JC Barrientos, NM Reddy, S Coutre, ... Blood, The Journal of the American Society of Hematology 133 (19), 2031-2042, 2019 | 245 | 2019 |
| Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA … AC Rawstron, KA Kreuzer, A Soosapilla, M Spacek, O Stehlikova, ... Cytometry Part B: Clinical Cytometry 94 (1), 121-128, 2018 | 227 | 2018 |
| Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases SP Mulligan, E Matutes, C Dearden, D Catovsky British journal of haematology 78 (2), 206-209, 1991 | 208 | 1991 |
| A variant form of hairy cell leukemia resistant to α-interferon: clinical and phenotypic characteristics of 17 patients L Sainati, E Matutes, S Mulligan, MP De Oliveira, S Rani, IA Lampert, ... Blood 76 (1), 157-162, 1990 | 179 | 1990 |
| Managing haematology and oncology patients during the COVID‐19 pandemic: interim consensus guidance R Weinkove, ZK McQuilten, J Adler, MR Agar, E Blyth, AC Cheng, ... Medical Journal of Australia 212 (10), 481-489, 2020 | 168 | 2020 |
| Identification of repertoires of surface antigens on leukemias using an antibody microarray L Belov, P Huang, N Barber, SP Mulligan, RI Christopherson Proteomics 3 (11), 2147-2154, 2003 | 156 | 2003 |
| Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL PM Barr, JR Brown, P Hillmen, S O'Brien, JC Barrientos, NM Reddy, ... Blood, The Journal of the American Society of Hematology 129 (19), 2612-2615, 2017 | 150 | 2017 |
| Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia JA Freeman, KR Crassini, OG Best, CJ Forsyth, NJ Mackinlay, P Han, ... Leukemia & lymphoma 54 (1), 99-104, 2013 | 127 | 2013 |
| Extensive surface protein profiles of extracellular vesicles from cancer cells may provide diagnostic signatures from blood samples L Belov, KJ Matic, S Hallal, OG Best, SP Mulligan, RI Christopherson Journal of extracellular vesicles 5 (1), 25355, 2016 | 124 | 2016 |
| Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray L Belov, SP Mulligan, N Barber, A Woolfson, M Scott, K Stoner, JS Chrisp, ... British journal of haematology 135 (2), 184-197, 2006 | 87 | 2006 |
| Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial M Dimopoulos, RG Sanz, HP Lee, M Trneny, M Varettoni, S Opat, S D'Sa, ... Blood advances 4 (23), 6009-6018, 2020 | 70 | 2020 |
| Screening microarrays of novel monoclonal antibodies for binding to T-, B-and myeloid leukaemia cells L Belov, P Huang, JS Chrisp, SP Mulligan, RI Christopherson Journal of immunological methods 305 (1), 10-19, 2005 | 68 | 2005 |
